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article under the CC BY-NC-ND licenseAbstract Peyronie’s disease (PD) is an acquired connective tissue disorder of the tunica al-
buginea of the corpus cavernosum, characterized by excessive fibrosis and plaque formation.
PD can result in significant physical and psychological morbidity; as it may prevent intercourse
and cause adverse impacts on partner relationships. The exact etiology and pathophysiology
remain unclear, and many misconceptions about the disease associations, course and treat-
ment exist.
The disease has two distinct stages. The acute stage is characterized by pain, and disease
may progress during this stage. Non-surgical managements at this stage aim to alleviate pain
and stabilize the disease. Results for non-surgical treatment are often conflicting. The chronic
stage occurs 6e12 months later, where pain disappears and the deformity stabilizes. Surgical
treatment is reserved for significant deformity or with inability to penetrative intercourse. The
choice of the surgical technique depends on the length of the penis, degree of deformity, erec-
tile function, patients’ expectations and surgeon’s preference.
ª 2015 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier
(Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Etiology and pathophysiology
Peyronie’s disease (PD) is an acquired connective tissue
disease of the tunica albuginea of the corpus cavernosum,
characterized by excessive fibrosis and plaque formation,
which do not expand like the normal tunica albugineaof Urology, King Abdul Aziz
com (A. Alwaal).
f Chinese Urological Associa-
.04.019
sian Journal of Urology. Productio
(http://creativecommons.org/licausing penile deformities in the erect state including
curvature, shortening, indentation and narrowing with a
hinge effect [1,2]. PD can result in significant physical and
psychological morbidity. Men may suffer from penile pain,
deformities and erectile dysfunction (ED) that prevent
sexual intercourse and reduce satisfaction, with adverse
impacts on partner relationships [3].
Recent reports showed that the prevalence of PD may be
up to 9%. However, the true prevalence may be under-
reported as some men may not seek medical advice due to
embarrassment or as a result of the false belief that the
condition is untreatable [4]. It typically affects males be-
tween 45 and 60 years [5]. However, 10% of patients whon and hosting by Elsevier (Singapore) Pte Ltd. This is an open access
censes/by-nc-nd/4.0/).
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agers [6,7]. Younger patients are more likely to present
earlier in the disease course, have pain, and more likely to
progress [8]. It is more common in younger Caucasian men
and after radical pelvic surgery, namely radical prostatec-
tomy [9]. PD is commonly associated with some comorbid
conditions and risk factors including diabetes, hypertension,
hyperlipidemia, ED, smoking, and excessive consumption of
alcohol [8,10,11]. PD occurs in 8% of type 2 diabetes mellitus
patients [12], 16% of patients who had radical prostatec-
tomy [9], and 20% of patients who have both diabetes and
ED [13]. Men with PD usually suffer significant distress and
nearly half of men with PD have mild or moderate depres-
sion [14,15]. Patients with PD are concerned about their
sexual attractiveness, self-image, sexual functioning and
performance. Anxiety, depression, low self-esteem and
relationship disorders were reported in more than half of
the patients [3,14e16]. The degree of distress does not
necessarily correlate with the degree of penile curvature or
deformity [15]. The natural history of PD varies; penile
curvature worsens in 30%e50% of patients, stabilizes in
47%e67%, while spontaneous improvement may occur in
3%e13% of patients [8,16,17].
Misconceptions about PD are very common, especially
among general practitioners, who are usually the initial
encounters of PD cases [4]. Common misconceptions
include the underestimation of PD, and the assumption that
it is only a disease of the elderly. Many believe that it is not
associated with ED and that no treatment is available, or it
will resolve for sure with time [4]. These misconceptions
represent obstacles to early treatment in the disease
course. Studies showed that earlier age of presentation
(40e50 years) and the presence of hypertension, diabetes
mellitus and dyslipidemia pose a greater risk for early dis-
ease progression [8]. Studies suggest also that early
detection and treatment may reduce psychological distress
[4]. Therefore, greater awareness of the natural history and
course of PD may promote early detection and prompt
treatment of the disease, and improve physical and psy-
chological outcomes in these men [4].
The exact etiology of PD is unknown. The most widely
accepted theory is trauma or repeated microtrauma to the
erect penis in genetically susceptible individuals. Repeated
microvascular traumatic injury to the tunica albuginea
causes inflammation, disruption of the elastic fibers and
deposition on fibrin [18,19]. This theory is also supported by
epidemiologic association of PD with some traumatic events
[20]. Some studies suggested that vascular trauma leads to
osteoid formation via osteoblast like cells originating from
the vascular lumen [20]. More recent reports showed that
upregulation of certain genes, namely, osteoblast specific
factor 1, may be responsible for plaque calcification [21].
Another theory is cavernosal hypoxia, which induces
collagen deposition and fibrosis. This may explain the
penile morphological changes and the development of PD
following radical prostatectomy [9].
Multiple pathways have been suggested although the
exact pathophysiology of PD remains unclear. PD has two
phases that may be distinguished by symptom presentation.
It starts with an acute inflammatory process characterized
by increased proliferation of the tunical fibroblasts, some
of which differentiate into myofibroblasts, with excessivedeposition of collagen. The transforming growth factor
(TGF)-b1 may play an important role in induction of
collagen production by fibroblasts/myofibroblasts in the
development of PD plaques [19,22]. Animal studies have
shown that TGF-b1 enhances collagen deposition and pla-
ques formation, while on the other hand suppressors of
TGF-b1 caused regression of the plaques [23,24]. Moreover,
overexpression of TGF-b1 was found in tissue samples from
human PD plaque [25]. The association of PD with Dupuyt-
ren’s contracture (in 20%e40% of cases) suggests a common
fibro-proliferative disorder [10,26]. The hallmark of this
stage is pain, which may occur either in the flaccid state or
as painful erections. It typically resolves after 12e18
months of the disease onset [17].
The second is the chronic or fibrotic phase. It usually
begins approximately 12e18 months following disease
onset. Pain typically disappears, and plaque and penile
deformity stabilize. At this stage, penile curvature and
deformity rarely improve [17]. One study found that PD
deformity stabilization was more likely among older pa-
tients and those who presented in the first 6 months of
symptoms, while improvement rates were higher among
younger patients [27]. Prolonged inflammation causes for-
mation of dense fibrotic plaques, which may progress to
calcification or ossification. The exact mechanism by which
tissue mineralization occurs remains uncertain [28]. Calci-
fication may be considered dystrophic in nature and may
result in penile curvature [19,29]. The incidence of calci-
fication currently varies widely, and most reports corre-
lated the presence of plaque calcification to disease
stabilization and severity [30]. In this context, improve-
ment of deformities can occur in the early stages of the
disease prior to dense calcification of the plaques [31].
However, a recent study found that calcified plaques were
detected as early as 6 weeks following the onset of symp-
toms, suggesting that it does not occur exclusively in the
setting of chronic or severe PD [29].
Some reports showed that patients with calcified pla-
ques are less responsive to non-surgical treatment modal-
ities and are more likely to progress to surgery [30,32,33].
However, these studies stratified patients according to the
presence of calcification or not rather than its extent. One
interesting study stratified patients according to the
maximum dimension of calcifications as they appear on
penile ultrasound; grade 1 (punctate or 0.3 cm), grade 2
(>0.3 cm and <1.5 cm) and grade 3 (1.5 cm or 2 plaques
>1.0 cm) [29]. This study demonstrated that not all pa-
tients with calcified plaques will need surgery, while those
with higher grades of calcification were more likely to have
surgery. Hence, stratifying patients according to the extent
of calcification may help prevent premature surgical
intervention and may serve as a clinical tool to counsel
patients on the odds of having surgery. This study also
found that plaque calcification was associated with older
age, penile deformity, and pain [29].2. Diagnosis
History and physical examination usually are satisfactory
for diagnosis. Symptoms usually differ according to the
disease phase, which will impact the decision for medical
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acute or the active stage of the disease, patients usually
report pain during erection. Pain is present in 35%e45% of
patients during the early stages of the disease, and usually
resolves during the first 12 months in more than 90% of
patients [10]. Also, patients may report a recent change in
penile curvature. The European guidelines recommend an
objective assessment of penile curvature during erection,
either by a home (self) photograph of a natural erection or
using a vacuum-assisted erection test or an intracavernosal
injection using vasoactive agents [10]. Risk factors for PD
(diabetes, hypertension, dyslipidemia, smoking, and
alcohol consumption) as well as the psychological burden
caused by the disease should also be determined.
ED is a common association in more than half of men
with PD. Erectile function can be assessed using validated
instruments such as the International Index of Erectile
Function (IIEF) [34]. It is crucial to assess erectile function
and elucidate the exact timing in relation to the onset of
PD, as this my influence further management of the patient
[35]. It may occur as a result of penile pain during erection,
functional disability as a result of the curvature or de-
formities, or due to psychological causes (performance
anxiety and fear of partner rejection) [16]. Arteriogenic ED
can still be detected, but veno-occlusive dysfunction re-
mains the main cause of erectile dysfunction in PD [36].
Sexual dysfunction may worsen over the natural course of
the disease [16].
The examination should start with a routine genitourinary
assessment. The penis should be examined for palpable
nodules or plaques, whose length should be measured at full
stretch and during erection. Also, assessment of the penile
length, rigidity, girth and curvature should also be done
during erection [10,31]. General examination should include
the hands and feet for detecting possible Dupuytren’s
contracture or Ledderhose scarring of the plantar fascia
[17], common associations with PD [10]. The end of the
acute phase is usually not easy to elucidate, but resolution
of pain and stability of the curvature for at least 3 months
are well accepted criteria of disease stabilization, and to
undertake surgical treatment if needed [16].
Among imaging modalities that have been described in
the literature, penile duplex ultrasonography remains the
preferred method of examination. It visualizes penile tis-
sues and detects areas of calcification. It is also a valuable
tool for hemodynamic assessment, as ED is a common as-
sociation with PD [31]. Although ultrasonographic mea-
surement of the plaque’s size is operator dependent and is
not recommended in the everyday clinical practice [10,37],
a recent study suggested that sorting patients according to
the extent of calcification of the plaques may be a valuable
tool in counseling and prognostication of patients with PD
[29].
3. Treatment
Determining the appropriate treatment depends on a vari-
ety of factors: the stage of the disease, the presence of
pain, severity and direction of the curvature, penile length,
and patient’s erectile status [4]. Optimal patient manage-
ment requires early detection and/or referral, to improvefunctional and psychological outcomes. Non-Surgical
treatments may be considered for patients in the acute
stage of the disease. Surgery is typically reserved for pa-
tients with stable disease [4].
3.1. Non-surgical treatment
Non-surgical treatment of PD targets the disease at the
early stage. It aims at alleviating penile pain, decreasing
disease progression, stabilizing inflammation, penile plaque
and deformity [38]. It includes oral pharmacotherapy,
intralesional injection therapy, and other topical treat-
ments. The results of the studies on conservative treatment
are often contradictory, complicating the process of pa-
tient counseling and decision making. Although preliminary
results for most of these therapies were promising, data
from randomized placebo-controlled studies failed to show
any benefit for many of them [10].
3.1.1. Oral treatment
3.1.1.1. Vitamin E. Vitamin E acts as a natural antioxidant
to reduce the number ofoxygen-free radicals producedduring
cellular metabolism. It is very popular among urologists being
available, safe and cheap. Despite its popularity in the
treatment of PD, a double blinded placebo-controlled study
failed to demonstrate any value in reduction of plaque size or
improvement of deformity [10].
3.1.1.2. Potassium para-aminobenzoate (Potaba). Potaba
decreases penile fibrosis by increasing oxygen uptake by the
tissues, enhancing the secretion of glycosaminoglycans, and
stimulating the activity of monoamine oxidases [39]. An early
prospective double-blinded controlled study showed that
Potaba significantly reduced penile pain but not penile
curvature or penile plaque size [40]. In a more recent
prospective randomized, double-blind, placebo-controlled
study, it was effective in decreasing penile plaque size and
stabilizing the penile curvature [41]. Side effects reported
include nausea, anorexia, pruritus, anxiety, chills, cold
sweats, confusion and difficulty concentrating [10].
3.1.1.3. Tamoxifen. Tamoxifen is a non-steroidal estrogen
receptor antagonist which is thought to modulate the
secretion of TGF-b1 secretion by fibroblasts. A placebo-
controlled, randomized study involving patients with
advanced disease failed to show any significant
improvement in pain, curvature, or plaque size in
patients with PD [42].
3.1.1.4. Colchicine. Colchicine is believed to be beneficial
in PD due to its anti-inflammatory effects. Studies showed
significant improvement in penile pain and curvature, with
reduction or disappearance of penile plaques [43,44]. A
combination of vitamin E and colchicine proved valuable
in early stage disease, with significant improvement in
plaque size and curvature [45]. Reported side effects
include gastrointestinal effects (nausea, vomiting,
diarrhea) that can be improved with dose escalation [44].
3.1.1.5. Acetyl esters of carnitine. Acetyl esters of
carnitine reduce penile fibrosis via decreasing intracellular
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tion and collagen production [46]. In a randomized, double-
blind study, acetyl-L-carnitine proved to be more effective
than tamoxifen with regards pain and curvature
improvement, and similar in decreasing the size of
plaques. Additionally, it showed also fewer side effects
[47].
3.1.1.6. Pentoxifylline. Pentoxifylline is a non-specific
phosphodiesterase inhibitor which inhibits TGF-b1 and
increases nitric oxide which appears to improve penile
curvature and stabilizes the process of mineralization
within the plaques [10]. Although the exact pathway by
which it stabilizes or decreases the mineralization is still
unclear, one study showed that it has no effect on elastin
production, but diminishes elastogenesis in tunica
albuginea-derived fibroblasts through an a1 antitrypsin-
dependent mechanism [48]. Moreover, pentoxifylline may
increase the microcirculation in the site of fibrotic and
calcified plaques, which may lead to a more rapid plaque
resolution and improvement in calcification over time
[49]. Improvement or stabilization in calcium burden
occurred in 92% of men treated withpentoxifylline, and
these men were also less likely to report subjective
worsening of their deformity [49]. Undesirable effects are
generally mild and include nausea, dizziness, and
headache [50].
3.1.1.7. Phosphodiesterase type 5 inhibitors (PDE5I). There
is a growing evidence for the beneficial effect of PDE5I in
PD. PDE5I may act by decreasing the ratio of collagen to
smooth muscles [51]. It can also augment the effect of
extracorporeal shock wave therapy (ESWT) on erectile
function in patients with PD [52].
3.1.1.8. Other oral therapies. Coenzyme Q10 is a fat-
soluble, vitamin-like quinine that is a powerful,
endogenously secreted antioxidant. In a randomized
control trial, it showed statistically significant
improvement in the IIEF score, mean plaque area, and
penile curvature at 6 months [53].
Omega-3 fatty acids (eicosapentonoic acid and docosa-
hexonoicacid) inhibit the release of inflammatory media-
tors and enhance collagenase activity. However, in a
randomized controlled trial it failed to show any benefit
over placebo [54].
3.1.2. Intralesional treatment
Another option is to directly inject the pharmacological
agent into the penile plaques. This ensures higher con-
centration inside the plaques while avoiding systemic side
effects.
3.1.2.1. Clostridial collagenase (Xiaflex). Clostridial
collagenase is a purified bacterial enzyme that selectively
breaks down collagen [55]. It is the only pharmacological
agent available that can break down the plaques and
therefore, improves the deformity. Xiaflex (collagenase
of Clostridium histolyticum, a product of Auxilium
Pharmaceuticals, Inc.) is only available through a Food
and Drug Administration (FDA) restricted program under aRisk Evaluation and Mitigation Strategy (REMS), with
trained healthcare professionals. Treatment course
constitutes a maximum of four cycles; each consists of
two injections and a penile modeling procedure. Within
each cycle, there should be a period of 1e3 days
between each injection, and between the second
injection and the penile modeling procedure (aiming at
relieving the curvature deformity and straightening the
penis). The interval between cycles should be around 6
weeks [56]. The injection procedure starts with marking
the target area of PD plaque in the erect state. The
injection itself should be done while the penis is flaccid,
where 0.58 mg is injected into the target plaque. This is
repeated 1e3 days later for the second injection, and
then followed by penile modeling procedure after further
1e3 days [56].
In previous studies, intralesional injection of clostridial
collagenase reduced penile plaques size and deformity
significantly especially for smaller plaques [57]. It was
found to be effective in improving the deformity in patients
with hourglass deformity, dorsal, and dorso-lateral curva-
tures but not ventral ones. In a double-blinded, placebo-
controlled study, Clostridial collagenase improved plaque
size and penile curvature in one third of the patients (in
comparison to only 4% in the placebo group) [57]. Better
response was achieved in patients with angulation less than
60 and plaque size smaller than 4 cm [57]. Adverse effects
include penile pain, contusions, ecchymosis, swelling,
redness and itching at or around the injection site [10].
3.1.2.2. Steroids. Intralesional steroids exert an anti-
inflammatory action via inhibition of phospholipase A2,
suppression of the immune response, and decreasing
collagen synthesis [10]. However, no statistically
significant improvement in deformity, plaque size or pain
was encountered in a single-blind, placebo-controlled
study [10]. Undesirable effects include thinning of the
skin and immunosuppression [58].
3.1.2.3. Verapamil. Verapamil is a calcium channel
blocker which inhibits the transport of extracellular matrix
proteins as collagen, fibronectin, and glycosaminoglycans.
It also enhances collagenases and inhibits fibroblasts pro-
liferation [59]. It may be useful for the treatment of acute
phase to stabilize disease progression or possibly reduce
penile deformity. Results from a single-blinded, placebo-
controlled study showed that at 6 months, plaque size
decreased significantly with a trend towards improvement
in penile curvature. Men with non-calcified plaques,
plaques smaller than 2.5 cm, angulation deformity less
than 30, and disease duration less than 2 years showed a
better response to intralesional verapamil [60]. Minor side
effects were reported including nausea, light headedness,
penile pain, and ecchymosis [10,61].
3.1.2.4. Interferon. Interferon-a2b inhibits fibroblast
proliferation and collagen production. Additionally, it is
thought to improve the healing of plaques [62]. Previous
studies showed its value in the improvement of pain,
plaque size and penile curvature [63]. A single-blinded,
placebo-controlled study showed that after over 12 weeks
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improvement) and penile curvature (27% improvement) in
treated patients when compared to placebo [64]. Side
effects include myalgia, arthralgia, sinusitis, fever and
flu-like symptoms [10].
3.1.3. Topical treatments
3.1.3.1. Topical verapamil. Topical verapamil gel signifi-
cantly diminished penile curvature, plaque size, and penile
pain, especially when applied for 6 months [65].
3.1.3.2. Iontophoresis (transdermal electromotive drug
administration [EMDA]). Studies showed improvement of
penile curvature, plaque size and penile pain during erection
[66]. In a randomized, double-blind, controlled study, a
combination of iontophoresis, verapamil 5 mg and
dexamethasone 8 mg resulted in improvement of penile
curvature and plaque size [67]. This method is not known to
be associated with any significant adverse event. Similarly, a
double-blinded, placebo-controlled trial of iontophoresis,
with and without verapamil, showed similar results between
the two groups. This study demonstrated an improvement of
50% or more in penile deformity, suggesting that the
electrical energy alone may be beneficial [67].
3.1.3.3. ESWT. There are two hypotheses for the mecha-
nism of action of ESWT in PD: shock waves may cause
damage of the penile plaque then induce remodeling; or it
enhances the vascularity of the area by induction of an
inflammatory reaction, increasing macrophage activity and
plaque destruction and absorption [68]. In a prospective,
randomized, double-blind, placebo controlled study, it
was associated with significant improvement in penile
pain but without improvement in penile curvature or
mean plaque size [69,70].
3.1.3.4. Traction devices. The concept is based on over-
stretching of the penile plaques, which causes an increase
in the degradative enzymes and loss of the tensile strength
and increased solubility, followed by remodeling [71]. One
study showed an improvement in penile curvature,
stretched penile length and erect girth in all men with no
adverse side effects or skin complications [72]. No
recommendations can be made based on the current
evidence.
3.1.3.5. Vacuum devices. Vacuum devices have the same
principles as traction devices. The use a vacuum device
improved penile pain, increased the stretched penile
length with an average of 0.5 cm, reduction of the curva-
ture in most of men [73].
3.2. Surgical treatment
When medical treatment fails to correct the deformity,
surgical treatment can be considered. Surgery aims at the
correction of curvature, maintaining satisfactory penile
length and rigidity to allow penetrative intercourse [4].
Surgery should be done only for patients with stable disease
for at least 12 months, although 3 months have been also
suggested [1,74,75]. Potential risks of surgery includepenile shortening, ED (higher risk with penile lengthening
procedures [1,76]), penile numbness, recurrent curvature
(due to surgery before disease stabilization, reactivation of
the condition, or the use of absorbable sutures [76]), the
potential for palpation of knots and stitches below the skin,
and the potential need for circumcision at the time of
surgery [1].
Procedures for correction of curvature due to PD are
either penile shortening or penile lengthening procedures
[76]. Penile shortening procedures are performed on the
convex (longer) side of the penis, while penile lengthening
procedures are performed on the concave (shorter) side of
the penis and require the use of a graft. The latter are
commonly used to avoid excessive penile shortening, or to
correct complex deformities [10]. The standard principles
of surgery for correction of PD include peniledegloving,
which may be combined with circumcision in many cases to
avoid post-operative phimosis [76]. Penile prosthesis should
be considered in PD associated with ED refractory to med-
ical treatment [77]. The choice of the surgical technique
depends on a number of factors, including penile length,
location and degree of curvature, erectile function, patient
goals and surgeon preference [1,4].
3.2.1. Penile shortening procedures
3.2.1.1. Nesbit technique. It involves removal of
5e10 mm transverse ellipses from the tunica albugineaor
approximately 1 mm for each 10 of curvature [78,79]. The
results of the Nesbit operation are excellent, where more
than 80% of men have complete straightening of the penis
after the procedure, with low risks for penile hypesthesia
or recurrence of penile deformity [80]. However, penile
shortening is the most commonly reported complication
[81], which is 1e1.5 cm in most of the cases, with no
gross impact on sexual intercourse [79,82]. Additionally,
the actual degree of shortening is usually less than that
perceived by the patient. Hence, the importance of
documenting the pre-operative penile length [80,81]. One
modification of the Nesbit procedure has been proposed,
where partial thickness of the tunica albuginea is done
instead of complete excision of a wedge from it [83].
3.2.1.2. Penile plication procedures. Results of the
plication procedures and satisfaction rates are very similar
to the Nesbit procedure [76]. Penile plication procedures
have the same principle as the Nesbit but are simpler to
perform. They are based on single or multiple longitudinal
incisions on the convex side of the penis, which are then
closed transversely (Heineke-Miculicz principle), or
plication without making any incision, or ‘16 dot’
technique [10]. The use of non-absorbable sutures may
decrease the failure rates [10].
3.2.2. Penile lengthening procedures
They involve incision of the short concave side of the penis,
lengthening it and creating a tunical defect, which is then
filled with a graft. Lengthening procedures provide a
reasonable choice for men with higher degree of curvature
(more than 60) and for those with hourglass deformity
[10]. Postoperative erectile dysfunction (as high as 25%) is a
common sequela due to venous leak [84]. Other
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the need for another surgery in about 17% of cases [85], and
penile shortening (although the risk is significantly less
compared with the aforementioned penile shortening pro-
cedures) [76]. Many grafting materials and techniques have
been proposed, but the ideal graft material is yet to be
determined (Table 1). One study showed that the presence
of pre-operative ED, larger graft size, age older than 60
years, and ventral curvature were associated with poor
functional outcome after grafting surgery [77].
Autologous grafts include saphenous vein, dermis, tunica
vaginalis, buccal mucosa, rectus fascia, temporalis fascia
and fascia lata [4,10]. Vein graft, saphenous vein is the
most common vein graft used, followed by the dorsal vein
of the penis [76]. Vein grafts have the theoretical advan-
tage of endothelial-to-endothelial contact when grafted to
the underlying cavernosal tissue. However, complications
reported include recurrent curvature (20%), penile short-
ening (17%) and graft herniation (5%) [10]. The use of Tunica
vaginalis has several potential advantages; it is relatively
avascular, easy to harvest and has a lower risk of contrac-
ture [86]. Contracture is a common complication for
Dermal grafts, which result in recurrent penile curvature
and penile shortening, with the need of surgical interven-
tion in 17% of cases at 10 years [87]. Disadvantages of
autologous grafts include additional donor-site morbidity
and increased operative time. Their outcomes are no better
than the more readily available allografts or xenografts
[88].
Allografts include cadaveric tissues as pericardium,
fascia lata, dura, and dermis [10]. Using cadaveric peri-
cardium, recurrence of curvature occurred in 44% of pa-
tients. However, most men in this study were satisfied and
reported successful sexual intercourse [87]. Xenografts, as
porcine small intestinal submucosa, provide a scaffold for
regeneration of host cells, and enhance angiogenesis and
remodeling. Although promising, no sufficient data are
available for any recommendations [89]. Synthetic mate-
rials are less favorable due to the increased risk of in-
fections [4].Table 1 Different types of grafts used in penile length-
ening procedures for surgical treatment of PD [10].
Type Grafts
Autologous grafts Dermis
Vein grafts
Tunica vaginalis
Temporalis fascia
Rectus fascia
Buccal mucosa
Allografts Cadaveric pericardium
Cadaveric fascia lata
Cadaveric dura matter
Cadaveric dermis
Xenografts Porcine small intestinal submucosa
Bovine pericardium
Porcine dermis
Synthetic grafts Gore-Tex
Dacron3.2.3. Penile prosthesis
Penile prosthesis implantation is done for men with PD
associated with ED, which is refractory to PDE5I [76]. It acts
as a tissue expander that will correct the curvature in few
months [90]. Implantation of a penile prosthesis may be
done with or without straightening maneuvers [1,38]. In a
minority of patients, with high degrees of curvature, penile
prosthesis implantation may be combined with penile
shortening or lengthening procedures to achieve complete
correction of the curvature [10]. The risk of complications
following penile prosthesis implantation is the same as the
general population [10].
3.2.4. Summary of the surgical treatment
Assessment of penile length, degree of the curvature and
erectile function status should be done for all patients. If
the degree of curvature is less than 60, a penile shortening
procedure is usually sufficient. If the degree of curvature is
more than 60 or is a complex curvature, or if the penile
length is short (with a good erectile function, with PDE5I or
without), penile lengthening procedure is appropriate.
However, if there is ED refractory to medical treatment,
penile prosthesis implantation is preferred. The latter may
be combined with an adjunct procedure in severe cases.
3.3. Potentials for the future e stem cell therapy
Regenerative urology represents a novel method with po-
tential benefits in the treatment of different urological
conditions including PD, with the use mesenchymal stem
cell therapy [91]. The external location of the penis makes
administration of local therapy, as stem cell therapy,
technically feasible and easy. Moreover, mesenchymal
pluripotent stem cells are readily available, and their use
avoids the ethical issues associated with the use of em-
bryonic stem cells. Also, autologous cells may be used,
avoiding the issue of antigenic incompatibility [92].
Adipose-derived stem-cell (ADSC) may be the most suitable
among mesenchymal stem cells, as they are abundant, and
easily accessible [92]. The exact mechanism of action for
ADSCs remain unclear; stem cells may differentiate and
replace the damaged tissue; increase the local production
of cytokines and growth factors; decrease inflammation
and oxidative stress; or modulate the extracellular matrix
[93]. One interesting finding is that ADSCs seem to migrate
to the site of injury, probably in response to cytokine
signaling [94].
In rats treated with intratunical injections TGF-b1, an
established model for PD, ADSCs inhibited the development
of PD. It decreased disordered collagen type III and elastin
tissues (common in PD plaques) [95], which could be the
basis for future research for their use in the treatment of
PD in humans and the hope of interrupting the disease
pathogenesis before it actually manifests.
4. Conclusion
PD is a common condition, whose exact etiology is still
unknown. Prevalence is higher among patients with dia-
betes and ED. The disease has an acute phase and a
chronic fibrotic phase. Early intervention is recommended
76 A.A. Hussein et al.to improve outcomes. Non-surgical treatments are indi-
cated for the acute phase to alleviate pain and stabilize
the curvature and deformity, among which intralesional
injection of clostridial collagenase seem the most effec-
tive. Surgical treatment is considered for stabilized dis-
ease for patients with severe deformities hindering sexual
intercourse, or cases with ED refractory to medical treat-
ment. Further research is needed to modulate the
different fibrotic agents and enhance stem cell therapy for
PD.
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